Evogene Statistics
Share Statistics
Evogene has 6.67M
shares outstanding. The number of shares has increased by -89.39%
in one year.
| Shares Outstanding | 6.67M |
| Shares Change (YoY) | -89.39% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 7.75% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 445 |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 177.98K, so 3.32% of the outstanding
shares have been sold short.
| Short Interest | 177.98K |
| Short % of Shares Out | 3.32% |
| Short % of Float | 3.33% |
| Short Ratio (days to cover) | 5.07 |
Valuation Ratios
The PE ratio is -0.65 and the forward
PE ratio is -0.78.
Evogene's PEG ratio is
0.01.
| PE Ratio | -0.65 |
| Forward PE | -0.78 |
| PS Ratio | 1.25 |
| Forward PS | 0.1 |
| PB Ratio | -7.34 |
| P/FCF Ratio | -0.52 |
| PEG Ratio | 0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Evogene.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15,
with a Debt / Equity ratio of -8.87.
| Current Ratio | 1.15 |
| Quick Ratio | 1.06 |
| Debt / Equity | -8.87 |
| Debt / EBITDA | -0.84 |
| Debt / FCF | -0.63 |
| Interest Coverage | -352.54 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $72,743.59 |
| Profits Per Employee | $-140,897.44 |
| Employee Count | 117 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 1.47 |
Taxes
| Income Tax | 9K |
| Effective Tax Rate | -0.05% |
Stock Price Statistics
The stock price has increased by -85.37% in the
last 52 weeks. The beta is 1.29, so Evogene's
price volatility has been higher than the market average.
| Beta | 1.29 |
| 52-Week Price Change | -85.37% |
| 50-Day Moving Average | 1.18 |
| 200-Day Moving Average | 1.87 |
| Relative Strength Index (RSI) | 40.79 |
| Average Volume (20 Days) | 380,083 |
Income Statement
In the last 12 months, Evogene had revenue of 8.51M
and earned -16.48M
in profits. Earnings per share was -2.89.
| Revenue | 8.51M |
| Gross Profit | 5.83M |
| Operating Income | -22.21M |
| Net Income | -16.48M |
| EBITDA | -15.38M |
| EBIT | -17.98M |
| Earnings Per Share (EPS) | -2.89 |
Full Income StatementBalance Sheet
The company has 15.3M in cash and 12.87M in
debt, giving a net cash position of 2.43M.
| Cash & Cash Equivalents | 15.3M |
| Total Debt | 12.87M |
| Net Cash | 2.43M |
| Retained Earnings | -274.07M |
| Total Assets | 39.86M |
| Working Capital | 2.89M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -19.7M
and capital expenditures -626K, giving a free cash flow of -20.33M.
| Operating Cash Flow | -19.7M |
| Capital Expenditures | -626K |
| Free Cash Flow | -20.33M |
| FCF Per Share | -3.57 |
Full Cash Flow StatementMargins
Gross margin is 68.48%, with operating and profit margins of -260.96% and -193.69%.
| Gross Margin | 68.48% |
| Operating Margin | -260.96% |
| Pretax Margin | -212.02% |
| Profit Margin | -193.69% |
| EBITDA Margin | -180.68% |
| EBIT Margin | -260.96% |
| FCF Margin | -238.82% |
